Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of AK117/AK112 in Combination With Chemotherapy for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer

NCT05227664 is registered in ClinicalTrials.gov with Akeso as lead sponsor.

NCT NCT05227664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05227664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of AK117/AK112 in Combination With Chemotherapy for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer
Lead sponsor
Akeso
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 23, 2022
Completion date
June 30, 2027
Enrollment
120 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced triple-negative breast cancer, metastatic triple-negative breast cancer